Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1714-21. doi: 10.1161/ATVBAHA.113.301538. Epub 2013 May 2.

Abstract

Objective: HIV patients on antiretroviral therapy (HIV/ART) exhibit a unique atherogenic dyslipidemic profile with hypertriglyceridemia (HTG) and low plasma concentrations of high-density lipoprotein (HDL) cholesterol. In the Heart Positive Study of HIV/ART patients, a hypolipidemic therapy of fenofibrate, niacin, diet, and exercise reduced HTG and plasma non-HDL cholesterol concentrations and raised plasma HDL cholesterol and adiponectin concentrations. We tested the hypothesis that HIV/ART HDL have abnormal structures and properties and are dysfunctional.

Approach and results: Hypolipidemic therapy reduced the TG contents of low-density lipoprotein and HDL. At baseline, HIV/ART low-density lipoproteins were more triglyceride (TG)-rich and HDL were more TG- and cholesteryl ester-rich than the corresponding lipoproteins from normolipidemic (NL) subjects. Very-low-density lipoproteins, low-density lipoprotein, and HDL were larger than the corresponding lipoproteins from NL subjects; HIV/ART HDL were less stable than NL HDL. HDL-[(3)H]cholesteryl ester uptake by Huh7 hepatocytes was used to assess HDL functionality. HIV/ART plasma were found to contain significantly less competitive inhibition activity for hepatocyte HDL-cholesteryl ester uptake than NL plasma were found to contain (P<0.001).

Conclusions: Compared with NL subjects, lipoproteins from HIV/ART patients are larger and more neutral lipid-rich, and their HDL are less stable and less receptor-competent. On the basis of this work and previous studies of lipase activity in HIV, we present a model in which plasma lipolytic activities or hepatic cholesteryl ester uptake are impaired in HIV/ART patients. These findings provide a rationale to determine whether the distinctive lipoprotein structure, properties, and function of HIV/ART HDL predict atherosclerosis as assessed by carotid artery intimal medial thickness.

Trial registration: ClinicalTrials.gov NCT00246376.

Keywords: HIV dyslipidemia; hepatocyte cholesteryl ester uptake; high-density lipoprotein function; lipoprotein composition.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Retroviral Agents / adverse effects*
  • Biomarkers / blood
  • Cell Line, Tumor
  • Cholesterol Esters / metabolism
  • Combined Modality Therapy
  • Diet
  • Exercise
  • Fibric Acids / therapeutic use
  • HIV Infections / blood
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy*
  • Hepatocytes / metabolism
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / chemically induced*
  • Hyperlipidemias / therapy
  • Hypolipidemic Agents / therapeutic use
  • Lipoproteins, HDL / blood*
  • Lipoproteins, LDL / blood
  • Lipoproteins, VLDL / blood
  • Niacin / therapeutic use
  • Protein Stability
  • Receptors, Lipoprotein / metabolism
  • Time Factors
  • Treatment Outcome
  • Triglycerides / blood

Substances

  • Anti-Retroviral Agents
  • Biomarkers
  • Cholesterol Esters
  • Fibric Acids
  • Hypolipidemic Agents
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Lipoproteins, VLDL
  • Receptors, Lipoprotein
  • Triglycerides
  • Niacin

Associated data

  • ClinicalTrials.gov/NCT00246376